Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-13

CYTOKINETICS INC (CYTK)

CEO Robert Blum was paid $11,881,456 in fiscal year 2025, ↓ down 17.3% from fiscal year 2024, the 53rd percentile of its disclosed peer group (SEC filing 0001140361-26-015364 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$11,881,456 ↓
Robert Blum total, FY2025
53rd
CEO pay percentile vs peers
1:1
CEO-to-median pay ratio
97.18%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Robert Blum (President and Chief Executive Officer), FY2025 total compensation $11,881,456 (base salary $853,069) [exec_comp, SEC accession 0001140361-26-015364, filed 2026-04-17]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

CYTK's next annual pay disclosure, estimated April 24, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Robert Blum$853,069$0$5,150,019$5,095,918$772,715$0$9,735$11,881,456
President and Chief Executive Officer
Jeffrey Hessekiel85,250200,0005,800,0130009546,086,217
Executive Vice President, Chief Legal and Administrative Officer
Fady Malik629,78101,750,0021,731,616335,144020,5234,467,066
Executive Vice President, Research and Development
Andrew Callos581,67801,449,9951,434,764302,960018,2473,787,644
Executive Vice President, Chief Commercial Officer
Sung Lee572,91801,449,9951,434,764295,608017,5223,770,807
Executive Vice President, Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Robert Blum$11,881,456$14,368,343$8,751,057↓ −2,486,887
Jeffrey Hessekiel6,086,217———
Fady Malik4,467,0665,371,3894,439,665↓ −904,323
Andrew Callos3,787,6444,389,0273,198,488↓ −601,383
Sung Lee3,770,8075,918,931—↓ −2,148,124

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read CYTOKINETICS INC's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CYTK reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the CYTOKINETICS INC Peer Teardown Report

$11,881,456 Robert Blum total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 13, 2026 · Source: 0001140361-26-015364 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for CYTK

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
CYTKon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order CYTK

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against CYTK
17 companies name CYTK as a compensation peer

Each company listed discloses CYTK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CYTK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the CYTOKINETICS INC Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Jeffrey HessekielGeneral Counsel$6,086,217
Andrew CallosCCO$3,787,644
Robert BlumCEO$11,881,456
Sung LeeCFO$3,770,807
Fady MalikEVP$4,467,066
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
B. Lynne ParshallIndependent Director$540,000
Edward M. KayeIndependent Director$478,815
Fiona BhanjiIndependent Director$520,750
John T. HendersonIndependent Director$480,294
Nancy J. WysenskiIndependent Director$501,338
Robert A. HarringtonIndependent Director$453,315
Robert E. DalyIndependent Director$721,563
Robert E. LandryIndependent Director$1,194,688
Wendell WierengaIndependent Director$504,588
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Fady MalikEVP Research & Development2026-04-21D3,500$0$0Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-04-21A3,500827,300CommonForm 4 ↗
Fady MalikEVP Research & Development2026-04-21D3,50066229,915CommonForm 4 ↗
Robert I. BlumDirector2026-04-29D7,50060447,150CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-04-30D15,00000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-04-30A15,00023348,900CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-04-30D15,00063948,900CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-01D15,85700Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-01A15,85738596,699CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-01D15,857651,030,705CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-05D11,33377875,474CommonForm 4 ↗
Wendell WierengaDirector2026-05-05D4,03200Derivative, Class A CommonForm 4 ↗
Wendell WierengaDirector2026-05-05D4,03275302,400CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-05D3,50077270,795CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-05A3,500827,300CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-05-05D23,906771,837,654CommonForm 4 ↗
John T. HendersonDirector2026-05-05D20,00000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-05D3,50000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-05D11,33300Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-05A11,33339443,460CommonForm 4 ↗
John T. HendersonDirector2026-05-05D20,000761,519,400CommonForm 4 ↗
Wendell WierengaDirector2026-05-05A4,0321249,997CommonForm 4 ↗
John T. HendersonDirector2026-05-05A20,0008152,200CommonForm 4 ↗
Robert I. BlumDirector2026-05-14D7,50078584,400CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-19D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-19D3,50076264,915CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-19A3,500827,300CommonForm 4 ↗
Nancy J. WysenskiDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Nancy J. WysenskiDirector2026-05-27A2,85100CommonForm 4 ↗
Wendell WierengaDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Robert E. LandryDirector2026-05-27A2,85100CommonForm 4 ↗
Edward M. KayeDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Edward M. KayeDirector2026-05-27A2,85100CommonForm 4 ↗
Robert A. HarringtonDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Robert E. DalyDirector2026-05-27A2,85100CommonForm 4 ↗
Fiona BhanjiDirector2026-05-27A2,85100CommonForm 4 ↗
Robert A. HarringtonDirector2026-05-27A2,85100CommonForm 4 ↗
Robert I. BlumDirector2026-05-27D7,50077579,075CommonForm 4 ↗
John T. HendersonDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
John T. HendersonDirector2026-05-27A2,85100CommonForm 4 ↗
Wendell WierengaDirector2026-05-27A2,85100CommonForm 4 ↗
B. Lynne ParshallDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
B. Lynne ParshallDirector2026-05-27A2,85100CommonForm 4 ↗
Robert E. DalyDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Fiona BhanjiDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Robert E. LandryDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-06-01D15,000741,111,200CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-06-01A15,00023348,900CommonForm 4 ↗
Edward M. KayeDirector2026-06-01D2,93376223,172CommonForm 4 ↗
B. Lynne ParshallDirector2026-06-01D5,00074370,400CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-06-01D15,00000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-09D3,50068237,930CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-09D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-09A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-06-15D7,50070528,450CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-23D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-23A3,500827,300CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-23D3,50080278,285CommonForm 4 ↗
Dividend-equivalent accruals2026-06-24—3,236——1 insider, 4 accrual rows
Sung LeeEVP, Chief Financial Officer2026-06-24D2,81700Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D9,30700Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D23,37000Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A23,370491,133,679CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A1,1134953,992CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A2,81744124,962CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D38,730823,187,479CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A8224436,464CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A188448,340CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A1,1134953,992CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A9,30744412,859CommonForm 4 ↗
Dividend-equivalent accruals2026-06-29—3,134——1 insider, 5 accrual rows
Sung LeeEVP, Chief Financial Officer2026-06-29D3,13485266,390CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A188448,340CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A1,1134953,992CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A8224436,464CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A188448,340CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A8234436,508CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-07-01A1,1124953,943CommonForm 4 ↗
Dividend-equivalent accruals2026-07-01—1,112——1 insider, 1 accrual row
Andrew CallosEVP, Chief Commercial Officer2026-07-01D15,00000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-01D15,000861,287,000CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-01A15,00023348,900CommonForm 4 ↗
Robert I. BlumDirector2026-07-01D7,50085636,900CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-07-01D1,1128897,622CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-07D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-07D3,50087303,170CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-07A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-07-13D7,49082614,330CommonForm 4 ↗
Robert I. BlumDirector2026-07-13D1082820CommonForm 4 ↗
Robert I. BlumDirector2026-07-13D7,49000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-07-13A7,4901179,394CommonForm 4 ↗
Robert E. DalyDirector2026-07-15A1518312,476CommonForm 4 ↗
Edward M. KayeDirector2026-07-15A1518312,476CommonForm 4 ↗
Nancy J. WysenskiDirector2026-07-15A75836,197CommonForm 4 ↗
Wendell WierengaDirector2026-07-15A75836,197CommonForm 4 ↗
Robert A. HarringtonDirector2026-07-15A1518312,476CommonForm 4 ↗
John T. HendersonDirector2026-07-15A2728322,473CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-21D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-21D3,50081282,065CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-21A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-07-27D7,50081606,525CommonForm 4 ↗
Robert I. BlumDirector2026-07-27A7,5001179,500CommonForm 4 ↗
Robert I. BlumDirector2026-07-27D7,50000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-30D14,00000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-30D14,000801,118,320CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-30A14,00023325,640CommonForm 4 ↗
Robert I. BlumDirector2026-08-10D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-08-10A7,5001179,500CommonForm 4 ↗
Robert I. BlumDirector2026-08-10D7,50077575,700CommonForm 4 ↗
Fady MalikEVP Research & Development2026-08-18D3,50076265,370CommonForm 4 ↗
Fady MalikEVP Research & Development2026-08-18A3,500827,300CommonForm 4 ↗
Fady MalikEVP Research & Development2026-08-18D3,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-08-31D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-08-31A7,5001179,500CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-08-31D10,00000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-08-31D10,00070702,400CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-08-31A10,00023232,600CommonForm 4 ↗
Robert I. BlumDirector2026-08-31D7,50070526,800CommonForm 4 ↗
B. Lynne ParshallDirector2026-09-01D5,00071357,400CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-08A3,500827,300CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-08D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-08D3,50075264,110CommonForm 4 ↗
Robert E. LandryDirector2026-09-11D1,0007574,660CommonForm 4 ↗
Robert I. BlumDirector2026-09-14D1,35000CommonForm 4 ↗
Robert I. BlumDirector2026-09-14D97,92600CommonForm 4 ↗
Robert I. BlumDirector2026-09-14D7,50073550,800CommonForm 4 ↗
Robert I. BlumDirector2026-09-14A7,5001179,500CommonForm 4 ↗
Robert I. BlumDirector2026-09-14D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-09-14A97,92600CommonForm 4 ↗
Robert E. LandryDirector2026-09-15D1,0007272,130CommonForm 4 ↗
Robert I. BlumDirector2026-09-15D97,926696,789,210CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-22D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-22D3,50068239,015CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-22A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-09-28D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-09-28D7,50065490,950CommonForm 4 ↗
Robert I. BlumDirector2026-09-28A7,5001179,500CommonForm 4 ↗
Fady MalikEVP Research & Development2026-10-06D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-10-06D3,50061214,830CommonForm 4 ↗
Fady MalikEVP Research & Development2026-10-06A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-10-12D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-10-12D7,50063471,600CommonForm 4 ↗
Robert I. BlumDirector2026-10-12A7,5001179,500CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 150 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Fady MalikEVP Research & Development2026-04-21D3,500$0$0Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-04-21A3,500827,300CommonForm 4 ↗
Fady MalikEVP Research & Development2026-04-21D3,50066229,915CommonForm 4 ↗
Robert I. BlumDirector2026-04-29D7,50060447,150CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-04-30D15,00000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-04-30A15,00023348,900CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-04-30D15,00063948,900CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-01D15,85700Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-01A15,85738596,699CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-01D15,857651,030,705CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-05D11,33377875,474CommonForm 4 ↗
Wendell WierengaDirector2026-05-05D4,03200Derivative, Class A CommonForm 4 ↗
Wendell WierengaDirector2026-05-05D4,03275302,400CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-05D3,50077270,795CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-05A3,500827,300CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-05-05D23,906771,837,654CommonForm 4 ↗
John T. HendersonDirector2026-05-05D20,00000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-05D3,50000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-05D11,33300Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-05-05A11,33339443,460CommonForm 4 ↗
John T. HendersonDirector2026-05-05D20,000761,519,400CommonForm 4 ↗
Wendell WierengaDirector2026-05-05A4,0321249,997CommonForm 4 ↗
John T. HendersonDirector2026-05-05A20,0008152,200CommonForm 4 ↗
Robert I. BlumDirector2026-05-14D7,50078584,400CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-19D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-19D3,50076264,915CommonForm 4 ↗
Fady MalikEVP Research & Development2026-05-19A3,500827,300CommonForm 4 ↗
Nancy J. WysenskiDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Nancy J. WysenskiDirector2026-05-27A2,85100CommonForm 4 ↗
Wendell WierengaDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Robert E. LandryDirector2026-05-27A2,85100CommonForm 4 ↗
Edward M. KayeDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Edward M. KayeDirector2026-05-27A2,85100CommonForm 4 ↗
Robert A. HarringtonDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Robert E. DalyDirector2026-05-27A2,85100CommonForm 4 ↗
Fiona BhanjiDirector2026-05-27A2,85100CommonForm 4 ↗
Robert A. HarringtonDirector2026-05-27A2,85100CommonForm 4 ↗
Robert I. BlumDirector2026-05-27D7,50077579,075CommonForm 4 ↗
John T. HendersonDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
John T. HendersonDirector2026-05-27A2,85100CommonForm 4 ↗
Wendell WierengaDirector2026-05-27A2,85100CommonForm 4 ↗
B. Lynne ParshallDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
B. Lynne ParshallDirector2026-05-27A2,85100CommonForm 4 ↗
Robert E. DalyDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Fiona BhanjiDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Robert E. LandryDirector2026-05-27A4,30100Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-06-01D15,000741,111,200CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-06-01A15,00023348,900CommonForm 4 ↗
Edward M. KayeDirector2026-06-01D2,93376223,172CommonForm 4 ↗
B. Lynne ParshallDirector2026-06-01D5,00074370,400CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-06-01D15,00000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-09D3,50068237,930CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-09D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-09A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-06-15D7,50070528,450CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-23D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-23A3,500827,300CommonForm 4 ↗
Fady MalikEVP Research & Development2026-06-23D3,50080278,285CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D1,11300Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D82200Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D1,11300Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D2,81700Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D9,30700Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D23,37000Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A23,370491,133,679CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A1,1134953,992CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A2,81744124,962CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D18800Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24D38,730823,187,479CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A8224436,464CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A188448,340CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A1,1134953,992CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-24A9,30744412,859CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29D18800Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29D3,13485266,390CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A188448,340CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A1,1134953,992CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A8224436,464CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29D1,11300Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A188448,340CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29D82300Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29D82200Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29D18800Derivative, Class A CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-06-29A8234436,508CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-07-01A1,1124953,943CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-07-01D1,11200Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-01D15,00000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-01D15,000861,287,000CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-01A15,00023348,900CommonForm 4 ↗
Robert I. BlumDirector2026-07-01D7,50085636,900CommonForm 4 ↗
Sung LeeEVP, Chief Financial Officer2026-07-01D1,1128897,622CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-07D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-07D3,50087303,170CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-07A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-07-13D7,49082614,330CommonForm 4 ↗
Robert I. BlumDirector2026-07-13D1082820CommonForm 4 ↗
Robert I. BlumDirector2026-07-13D7,49000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-07-13A7,4901179,394CommonForm 4 ↗
Robert E. DalyDirector2026-07-15A1518312,476CommonForm 4 ↗
Edward M. KayeDirector2026-07-15A1518312,476CommonForm 4 ↗
Nancy J. WysenskiDirector2026-07-15A75836,197CommonForm 4 ↗
Wendell WierengaDirector2026-07-15A75836,197CommonForm 4 ↗
Robert A. HarringtonDirector2026-07-15A1518312,476CommonForm 4 ↗
John T. HendersonDirector2026-07-15A2728322,473CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-21D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-21D3,50081282,065CommonForm 4 ↗
Fady MalikEVP Research & Development2026-07-21A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-07-27D7,50081606,525CommonForm 4 ↗
Robert I. BlumDirector2026-07-27A7,5001179,500CommonForm 4 ↗
Robert I. BlumDirector2026-07-27D7,50000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-30D14,00000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-30D14,000801,118,320CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-07-30A14,00023325,640CommonForm 4 ↗
Robert I. BlumDirector2026-08-10D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-08-10A7,5001179,500CommonForm 4 ↗
Robert I. BlumDirector2026-08-10D7,50077575,700CommonForm 4 ↗
Fady MalikEVP Research & Development2026-08-18D3,50076265,370CommonForm 4 ↗
Fady MalikEVP Research & Development2026-08-18A3,500827,300CommonForm 4 ↗
Fady MalikEVP Research & Development2026-08-18D3,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-08-31D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-08-31A7,5001179,500CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-08-31D10,00000Derivative, Class A CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-08-31D10,00070702,400CommonForm 4 ↗
Andrew CallosEVP, Chief Commercial Officer2026-08-31A10,00023232,600CommonForm 4 ↗
Robert I. BlumDirector2026-08-31D7,50070526,800CommonForm 4 ↗
B. Lynne ParshallDirector2026-09-01D5,00071357,400CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-08A3,500827,300CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-08D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-08D3,50075264,110CommonForm 4 ↗
Robert E. LandryDirector2026-09-11D1,0007574,660CommonForm 4 ↗
Robert I. BlumDirector2026-09-14D1,35000CommonForm 4 ↗
Robert I. BlumDirector2026-09-14D97,92600CommonForm 4 ↗
Robert I. BlumDirector2026-09-14D7,50073550,800CommonForm 4 ↗
Robert I. BlumDirector2026-09-14A7,5001179,500CommonForm 4 ↗
Robert I. BlumDirector2026-09-14D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-09-14A97,92600CommonForm 4 ↗
Robert E. LandryDirector2026-09-15D1,0007272,130CommonForm 4 ↗
Robert I. BlumDirector2026-09-15D97,926696,789,210CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-22D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-22D3,50068239,015CommonForm 4 ↗
Fady MalikEVP Research & Development2026-09-22A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-09-28D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-09-28D7,50065490,950CommonForm 4 ↗
Robert I. BlumDirector2026-09-28A7,5001179,500CommonForm 4 ↗
Fady MalikEVP Research & Development2026-10-06D3,50000Derivative, Class A CommonForm 4 ↗
Fady MalikEVP Research & Development2026-10-06D3,50061214,830CommonForm 4 ↗
Fady MalikEVP Research & Development2026-10-06A3,500827,300CommonForm 4 ↗
Robert I. BlumDirector2026-10-12D7,50000Derivative, Class A CommonForm 4 ↗
Robert I. BlumDirector2026-10-12D7,50063471,600CommonForm 4 ↗
Robert I. BlumDirector2026-10-12A7,5001179,500CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Robert BlumRSU2025-03-15——116,096—$5,150,019
Sung LeeRSU2025-03-15——32,687—1,449,995
Fady MalikRSU2025-03-15——39,450—1,750,002
Sung LeeOPTION2025-03-15——48,497—1,434,764
Robert BlumOPTION2025-03-15——172,249—5,095,918
Andrew CallosRSU2025-03-15——32,687—1,449,995
Andrew CallosOPTION2025-03-15——48,497—1,434,764
Jeffrey HessekielRSU2025-11-15——87,297—5,800,013
Fady MalikOPTION2025-03-15——58,531—1,731,616
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Robert Blum$5,150,019$0$5,095,9180.0%
Sung Lee1,449,99501,434,7640.0%
Fady Malik1,750,00201,731,6160.0%
Andrew Callos1,449,99501,434,7640.0%
Jeffrey Hessekiel5,800,013000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Sung LeeRSU32,687—$2,076,932
Andrew CallosRSU6,000—381,240
Robert BlumOption39,95663.75—
Andrew CallosRSU10,164—645,821
Robert BlumRSU16,500—1,048,410
Andrew CallosRSU1,589—100,933
Robert BlumOption51,56339.13—
Sung LeeRSU20,810—1,322,267
Robert BlumRSU5,765—366,308
Sung LeeOption32,27348.51—
Robert BlumRSU116,096—7,376,740
Sung LeeRSU2,152—136,706
Andrew CallosOption15,62539.13—
Robert BlumRSU36,894—2,344,245
Robert BlumOption11,25037.63—
Andrew CallosOption39,40444.36—
Andrew CallosOption11,00963.75—
Andrew CallosOption2,81337.63—
Andrew CallosRSU32,687—2,076,932
Sung LeeOption39,40444.36—
Jeffrey HessekielRSU87,297—5,546,851
Robert BlumOption139,95344.36—
05

Incentive-plan design — the Compensation Discussion & Analysis

The Compensation Committee aims to provide target total cash and long-term equity compensation at or around the median of the compensation paid to similarly situated executives employed by the Peer Companies for target level performance, with compensation above this level possible for exceptional performance.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)—
Independent consultantAon Human Capital Solutions
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-27104,005,5313,018,095844,59297.18%Passed
20252025-05-1496,760,2724,607,831250,93795.45%Passed
20242024-05-1585,814,3952,927,007790,69396.7%Passed
20232023-05-1083,090,3173,278,668147,61296.04%Passed
20222022-05-1071,536,8132,039,137446,40596.64%Passed
20212021-05-1255,993,2322,372,911285,58295.47%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2797.18%a
20252025-05-1495.45%b
20242024-05-1596.7%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)1 : 1
CEO total compensation$11,881,456
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Robert E. LandryIndependent · Audit$54,688$220,000$920,000$0$0$1,194,688
Robert E. DalyIndependent · Compliance · Newly elected21,563—700,00000721,563
B. Lynne ParshallIndependent · Audit (Chair) · Compliance · Transactions (Chair)100,000220,000220,00000540,000
Fiona BhanjiIndependent · Nominating/Governance · Compliance (Chair) · Transactions80,750220,000220,00000520,750
Wendell WierengaIndependent · Compensation and Talent · Nominating/Governance · Science and Technology (Chair)64,588220,000220,00000504,588
Nancy J. WysenskiIndependent · Compensation and Talent (Chair) · Compliance · Transactions61,338220,000220,00000501,338
John T. HendersonIndependent · Audit · Nominating/Governance (Chair) · Science and Technology · Transactions40,294220,000220,00000480,294
Edward M. KayeIndependent · Audit · Compensation and Talent · Science and Technology · Transactions38,815220,000220,00000478,815
Robert A. HarringtonIndependent · Nominating/Governance · Science and Technology13,315220,000220,00000453,315
Robert I. BlumEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$440,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)10,000 / 10,000
Stock ownership guideline3x annual cash retainer (committee retainers excluded) for non-executive directors
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$475,351
Equity awards (grant-date value)$1,760,000
All other compensation$0
Total cost of the board$2,235,351

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies CYTOKINETICS INC names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including CYTOKINETICS INC.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Halozyme Therapeutics, Inc.2025Helen Torley$1,000,000$19,350,145$1,650,014$1,147,500$23,166,223
2Immunovant, Inc.2026Eric Venker636,618019,010,639020,158,767
3Madrigal Pharmaceuticals, Inc.2025Bill Sibold918,53112,297,8504,537,1461,438,81419,206,341
4BridgeBio Pharma, Inc.2025Neil Kumar1,044,00010,606,2751,874,992014,944,585
5INSMED Inc.2025William Lewis854,5502,999,9409,000,0331,495,46314,467,393
6Vaxcyte, Inc.2025Grant Pickering800,0004,300,1598,714,048630,00014,458,937
7Blueprint Medicines Corporation2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
8Ionis Pharmaceuticals, Inc.2025Brett Monia1,051,7768,444,8381,438,105013,350,777
9ImmunityBio, Inc.2025Richard Adcock831,6672,787,8288,353,406485,16612,716,953
10CYTOKINETICS INC2025Robert Blum853,0695,150,0195,095,918772,71511,881,456
11Crinetics Pharmaceuticals, Inc.2025R. Scott Struthers718,5003,280,5407,160,564462,35511,628,959
12Ultragenyx Pharmaceuticals Inc.2025Emil Kakkis861,1008,364,9381,847,356299,66311,405,535
13Apellis Pharmaceuticals, Inc.2024Cedric Francois793,1934,779,8324,787,768010,957,451
14Axsome Therapeutics, Inc.2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
15Intra-Cellular Therapies, Inc.2023Sharon Mates891,6537,749,9840010,086,413
16Arrowhead Pharmaceuticals, Inc.2025Christopher Anzalone981,0466,810,29201,236,0009,029,861
17Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
18ACADIA Pharmaceuticals Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
19Sarepta Therapeutics, Inc.2025Douglas Ingram1,171,4256,000,0050649,0007,840,666
20Denali Therapeutics Inc.2025Ryan Watts718,0001,151,8672,180,00304,751,515
—Ascendis Pharma A/S——————not in coverage universe
—Legend Biotech Corp——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
CYTOKINETICS INC120%RSU 50 · Options 50not disclosedAon Human Capital Solutions
ACADIA Pharmaceuticals Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Apellis Pharmaceuticals, Inc.90.74%RSU 50 · PSU 50not disclosedPay Governance
Arrowhead Pharmaceuticals, Inc.125%PSU 70 · RSU 30not disclosedCompensia
Ascendis Pharma A/Snot disclosednot disclosednot disclosednot disclosed
Axsome Therapeutics, Inc.150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
Blueprint Medicines Corporation130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon
BridgeBio Pharma, Inc.135%RSU 50 · PSU 35 · Options 15NoAon Talent Solutions
Crinetics Pharmaceuticals, Inc.not disclosedOptions 70 · RSU 30not disclosedPearl Meyer
Denali Therapeutics Inc.145%not disclosednot disclosedAlpine Rewards
Halozyme Therapeutics, Inc.127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
ImmunityBio, Inc.not disclosedOptions 75 · RSU 25not disclosedMercer
Immunovant, Inc.110%not disclosedNoCompensia
INSMED Inc.175%Options 75 · RSU 25NoWillis Towers Watson (WTW)
Intra-Cellular Therapies, Inc.not disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Ionis Pharmaceuticals, Inc.not disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Legend Biotech Corpnot disclosednot disclosednot disclosednot disclosed
Madrigal Pharmaceuticals, Inc.195%PSU 33 · RSU 33 · Options 33Yes — Relative TSR vs Nasdaq Biotechnology IndexCompensia
Sarepta Therapeutics, Inc.100%PSU 50 · Option 25 · RSU 25NoFW Cook
Ultragenyx Pharmaceuticals Inc.44%PSU 60 · RSU 20 · Options 20Yes — Relative TSRAon's Human Capital Solutions Practice
Vaxcyte, Inc.105%not disclosednot disclosedPay Governance

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at CYTOKINETICS INC in fiscal 2025?
As disclosed, Robert Blum (President and Chief Executive Officer) was the highest-paid executive at CYTOKINETICS INC in fiscal 2025, with total compensation of $11,881,456.
How does CYTOKINETICS INC's chief executive pay compare to its disclosed peer group?
As disclosed, Robert Blum's total compensation ranked at the 53rd percentile of CYTOKINETICS INC's disclosed peer group.
What is CYTOKINETICS INC's CEO-to-median employee pay ratio?
As disclosed, CYTOKINETICS INC's CEO-to-median employee pay ratio was 1:1.
How did shareholders vote on CYTOKINETICS INC's executive compensation?
As disclosed, 97.18% of shareholders supported CYTOKINETICS INC's executive compensation in the latest say-on-pay vote.
How much does CYTOKINETICS INC spend in total on board compensation for fiscal 2025?
As disclosed, CYTOKINETICS INC reported total board compensation of $2,235,351 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Robert BlumDEF 14A2026-04-170001140361-26-015364Section “Executive Summary Compensation Table for 2025”. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103
2Section 01, Jeffrey HessekielDEF 14A2026-04-170001140361-26-015364Section “Executive Summary Compensation Table for 2025”. As printed: 6,086,217. Filing ↗machine: r8 · c25 · span 806202–806211
3Section 01, Fady MalikDEF 14A2026-04-170001140361-26-015364Section “Executive Summary Compensation Table for 2025”. As printed: 4,467,066. Filing ↗machine: r11 · c25 · span 820906–820915
4Section 01, Andrew CallosDEF 14A2026-04-170001140361-26-015364Section “Executive Summary Compensation Table for 2025”. As printed: 3,787,644. Filing ↗machine: r5 · c25 · span 791561–791570
5Section 01, Sung LeeDEF 14A2026-04-170001140361-26-015364Section “Executive Summary Compensation Table for 2025”. As printed: 3,770,807. Filing ↗machine: r9 · c25 · span 811013–811022
6Section 03, Robert Blum RSUDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r4 · c16 · span 864649–864656
7Section 03, Sung Lee RSUDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r12 · c16 · span 904946–904952
8Section 03, Fady Malik RSUDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r15 · c16 · span 919905–919911
9Section 03, Sung Lee OPTIONDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r13 · c19 · span 911039–911045
10Section 03, Robert Blum OPTIONDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r5 · c19 · span 870700–870707
11Section 03, Andrew Callos RSUDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r7 · c16 · span 879676–879682
12Section 03, Andrew Callos OPTIONDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r8 · c19 · span 884959–884965
13Section 03, Jeffrey Hessekiel RSUDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r10 · c16 · span 894294–894300
14Section 03, Fady Malik OPTIONDEF 14A2026-04-170001140361-26-015364Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t217 · r16 · c19 · span 924340–924346
15Section 07, pay ratioDEF 14A2026-04-170001140361-26-015364Section “CEO Pay Ratio”. As printed: 1 : 1. Filing ↗machine: t249 · r1 · c4 · span 1262492–1262503
16Section 08, Robert E. LandryDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 1,194,688. Filing ↗machine: t283 · r7 · c13 · span 1478510–1478672
17Section 08, Robert E. DalyDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 721,563. Filing ↗machine: t283 · r4 · c13 · span 1470996–1471199
18Section 08, B. Lynne ParshallDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 540,000. Filing ↗machine: t283 · r8 · c13 · span 1481167–1481370
19Section 08, Fiona BhanjiDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 520,750. Filing ↗machine: t283 · r3 · c13 · span 1468217–1468420
20Section 08, Wendell WierengaDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 504,588. Filing ↗machine: t283 · r9 · c13 · span 1483556–1483759
21Section 08, Nancy J. WysenskiDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 501,338. Filing ↗machine: t283 · r10 · c13 · span 1486176–1486378
22Section 08, John T. HendersonDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 480,294. Filing ↗machine: t283 · r2 · c13 · span 1465830–1466033
23Section 08, Edward M. KayeDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 478,815. Filing ↗machine: t283 · r6 · c13 · span 1476123–1476326
24Section 08, Robert A. HarringtonDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 453,315. Filing ↗machine: t283 · r5 · c13 · span 1473387–1473590
25Section 08, Robert I. BlumDEF 14A2026-04-170001140361-26-015364Section “Director Compensation”. As printed: 0. Filing ↗
26Section 02, Fady Malik 2026-04-21Form 42026-04-210001061983-26-000043Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Fady Malik 2026-04-21Form 42026-04-210001061983-26-000043Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Fady Malik 2026-04-21Form 42026-04-210001061983-26-000043Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Robert I. Blum 2026-04-29Form 42026-04-290001061983-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Andrew Callos 2026-04-30Form 42026-04-300001061983-26-000045Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Andrew Callos 2026-04-30Form 42026-04-300001061983-26-000045Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Andrew Callos 2026-04-30Form 42026-04-300001061983-26-000045Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Andrew Callos 2026-05-01Form 42026-05-040001061983-26-000046Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Andrew Callos 2026-05-01Form 42026-05-040001061983-26-000046Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Andrew Callos 2026-05-01Form 42026-05-040001061983-26-000046Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Andrew Callos 2026-05-05Form 42026-05-050001061983-26-000047Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Wendell Wierenga 2026-05-05Form 42026-05-050001061983-26-000050Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Wendell Wierenga 2026-05-05Form 42026-05-050001061983-26-000050Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Fady Malik 2026-05-05Form 42026-05-050001061983-26-000051Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Fady Malik 2026-05-05Form 42026-05-050001061983-26-000051Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Sung Lee 2026-05-05Form 42026-05-050001061983-26-000049Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, John T. Henderson 2026-05-05Form 42026-05-050001061983-26-000048Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Fady Malik 2026-05-05Form 42026-05-050001061983-26-000051Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Andrew Callos 2026-05-05Form 42026-05-050001061983-26-000047Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Andrew Callos 2026-05-05Form 42026-05-050001061983-26-000047Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, John T. Henderson 2026-05-05Form 42026-05-050001061983-26-000048Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Wendell Wierenga 2026-05-05Form 42026-05-050001061983-26-000050Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, John T. Henderson 2026-05-05Form 42026-05-050001061983-26-000048Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Robert I. Blum 2026-05-14Form 42026-05-140001061983-26-000052Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Fady Malik 2026-05-19Form 42026-05-200001061983-26-000053Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Fady Malik 2026-05-19Form 42026-05-200001061983-26-000053Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Fady Malik 2026-05-19Form 42026-05-200001061983-26-000053Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Nancy J. Wysenski 2026-05-27Form 42026-05-270001061983-26-000054Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Nancy J. Wysenski 2026-05-27Form 42026-05-270001061983-26-000054Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Wendell Wierenga 2026-05-27Form 42026-05-270001061983-26-000055Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Robert E. Landry 2026-05-27Form 42026-05-270001061983-26-000056Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Edward M. Kaye 2026-05-27Form 42026-05-270001061983-26-000058Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Edward M. Kaye 2026-05-27Form 42026-05-270001061983-26-000058Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Robert A. Harrington 2026-05-27Form 42026-05-270001061983-26-000060Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Robert E. Daly 2026-05-27Form 42026-05-270001061983-26-000061Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Fiona Bhanji 2026-05-27Form 42026-05-270001061983-26-000062Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Robert A. Harrington 2026-05-27Form 42026-05-270001061983-26-000060Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Robert I. Blum 2026-05-27Form 42026-05-280001061983-26-000063Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, John T. Henderson 2026-05-27Form 42026-05-270001061983-26-000059Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, John T. Henderson 2026-05-27Form 42026-05-270001061983-26-000059Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Wendell Wierenga 2026-05-27Form 42026-05-270001061983-26-000055Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, B. Lynne Parshall 2026-05-27Form 42026-05-270001061983-26-000057Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, B. Lynne Parshall 2026-05-27Form 42026-05-270001061983-26-000057Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Robert E. Daly 2026-05-27Form 42026-05-270001061983-26-000061Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Fiona Bhanji 2026-05-27Form 42026-05-270001061983-26-000062Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Robert E. Landry 2026-05-27Form 42026-05-270001061983-26-000056Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Andrew Callos 2026-06-01Form 42026-06-010001061983-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Andrew Callos 2026-06-01Form 42026-06-010001061983-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Edward M. Kaye 2026-06-01Form 42026-06-010001061983-26-000066Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, B. Lynne Parshall 2026-06-01Form 42026-06-010001061983-26-000064Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Andrew Callos 2026-06-01Form 42026-06-010001061983-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Fady Malik 2026-06-09Form 42026-06-090001061983-26-000067Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Fady Malik 2026-06-09Form 42026-06-090001061983-26-000067Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Fady Malik 2026-06-09Form 42026-06-090001061983-26-000067Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Robert I. Blum 2026-06-15Form 42026-06-150001061983-26-000068Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Fady Malik 2026-06-23Form 42026-06-230001061983-26-000069Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Fady Malik 2026-06-23Form 42026-06-230001061983-26-000069Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Fady Malik 2026-06-23Form 42026-06-230001061983-26-000069Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Sung Lee 2026-06-24Form 42026-06-290001061983-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Sung Lee 2026-06-29Form 42026-06-290001061983-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Sung Lee 2026-07-01Form 42026-07-020001061983-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Sung Lee 2026-07-01Form 42026-07-020001061983-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Andrew Callos 2026-07-01Form 42026-07-020001061983-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Andrew Callos 2026-07-01Form 42026-07-020001061983-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Andrew Callos 2026-07-01Form 42026-07-020001061983-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Robert I. Blum 2026-07-01Form 42026-07-020001061983-26-000074Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Sung Lee 2026-07-01Form 42026-07-020001061983-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Fady Malik 2026-07-07Form 42026-07-070001061983-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Fady Malik 2026-07-07Form 42026-07-070001061983-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Fady Malik 2026-07-07Form 42026-07-070001061983-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Robert I. Blum 2026-07-13Form 42026-07-140001061983-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Robert I. Blum 2026-07-13Form 42026-07-140001061983-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Robert I. Blum 2026-07-13Form 42026-07-140001061983-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Robert I. Blum 2026-07-13Form 42026-07-140001061983-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Robert E. Daly 2026-07-15Form 42026-07-160001061983-26-000078Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Edward M. Kaye 2026-07-15Form 42026-07-160001061983-26-000081Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Nancy J. Wysenski 2026-07-15Form 42026-07-160001061983-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Wendell Wierenga 2026-07-15Form 42026-07-160001061983-26-000082Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Robert A. Harrington 2026-07-15Form 42026-07-160001061983-26-000079Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, John T. Henderson 2026-07-15Form 42026-07-160001061983-26-000080Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Fady Malik 2026-07-21Form 42026-07-230001061983-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Fady Malik 2026-07-21Form 42026-07-230001061983-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Fady Malik 2026-07-21Form 42026-07-230001061983-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Robert I. Blum 2026-07-27Form 42026-07-270001061983-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Robert I. Blum 2026-07-27Form 42026-07-270001061983-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Robert I. Blum 2026-07-27Form 42026-07-270001061983-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Andrew Callos 2026-07-30Form 42026-07-300001061983-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Andrew Callos 2026-07-30Form 42026-07-300001061983-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Andrew Callos 2026-07-30Form 42026-07-300001061983-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Robert I. Blum 2026-08-10Form 42026-08-100001061983-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Robert I. Blum 2026-08-10Form 42026-08-100001061983-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Robert I. Blum 2026-08-10Form 42026-08-100001061983-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Fady Malik 2026-08-18Form 42026-08-180001061983-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Fady Malik 2026-08-18Form 42026-08-180001061983-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Fady Malik 2026-08-18Form 42026-08-180001061983-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Robert I. Blum 2026-08-31Form 42026-08-310001061983-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Robert I. Blum 2026-08-31Form 42026-08-310001061983-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Andrew Callos 2026-08-31Form 42026-08-310001061983-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Andrew Callos 2026-08-31Form 42026-08-310001061983-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Andrew Callos 2026-08-31Form 42026-08-310001061983-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Robert I. Blum 2026-08-31Form 42026-08-310001061983-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, B. Lynne Parshall 2026-09-01Form 42026-09-010001061983-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Fady Malik 2026-09-08Form 42026-09-080001061983-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Fady Malik 2026-09-08Form 42026-09-080001061983-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Fady Malik 2026-09-08Form 42026-09-080001061983-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Robert E. Landry 2026-09-11Form 42026-09-110001061983-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Robert I. Blum 2026-09-14Form 42026-09-150001061983-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Robert I. Blum 2026-09-14Form 42026-09-150001061983-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Robert I. Blum 2026-09-14Form 42026-09-150001061983-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Robert I. Blum 2026-09-14Form 42026-09-150001061983-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Robert I. Blum 2026-09-14Form 42026-09-150001061983-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Robert I. Blum 2026-09-14Form 42026-09-150001061983-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Robert E. Landry 2026-09-15Form 42026-09-150001061983-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Robert I. Blum 2026-09-15Form 42026-09-150001061983-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Fady Malik 2026-09-22Form 42026-09-220001061983-26-000096Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Fady Malik 2026-09-22Form 42026-09-220001061983-26-000096Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Fady Malik 2026-09-22Form 42026-09-220001061983-26-000096Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Robert I. Blum 2026-09-28Form 42026-09-280001061983-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Robert I. Blum 2026-09-28Form 42026-09-280001061983-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Robert I. Blum 2026-09-28Form 42026-09-280001061983-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Fady Malik 2026-10-06Form 42026-10-060001061983-26-000098Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Fady Malik 2026-10-06Form 42026-10-060001061983-26-000098Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Fady Malik 2026-10-06Form 42026-10-060001061983-26-000098Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Robert I. Blum 2026-10-12Form 42026-10-130001061983-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Robert I. Blum 2026-10-12Form 42026-10-130001061983-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Robert I. Blum 2026-10-12Form 42026-10-130001061983-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
176Section 06, 2026 voteForm 8-K2026-05-270001193125-26-241840Item 5.07 · say-on-pay result. As reported: 97.18% (votes for as printed: 104,005,531). Filing ↗
177Section 06, 2025 voteForm 8-K2025-05-160000950170-25-072965Item 5.07 · say-on-pay result. As reported: 95.45% (votes for as printed: 96,760,272). Filing ↗
178Section 06, 2024 voteForm 8-K2024-05-170000950170-24-061275Item 5.07 · say-on-pay result. As reported: 96.7% (votes for as printed: 85,814,395). Filing ↗
179Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
180Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
181Section 09b board cost (computed)Computed——Cash 475,351 + equity 1,760,000 + all other 0 = 2,235,351, summed across the director compensation table rows.machine: formula: Σ = 2,235,351
182Halozyme Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
183Immunovant, Inc., Section 10b CEO totalDEF 14A2026-07-220001764013-26-000092CEO total compensation as printed in Immunovant, Inc.'s own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726
184Madrigal Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-280001308179-26-000352CEO total compensation as printed in Madrigal Pharmaceuticals, Inc.'s own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952
185BridgeBio Pharma, Inc., Section 10b CEO totalDEF 14A2026-04-240001140361-26-016723CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531
186INSMED Inc., Section 10b CEO totalDEF 14A2026-04-010001104506-26-000022CEO total compensation as printed in INSMED Inc.'s own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563
187Vaxcyte, Inc., Section 10b CEO totalDEF 14A2026-04-230001193125-26-173672CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207
188Blueprint Medicines Corporation, Section 10b CEO totalDEF 14A2025-04-240001558370-25-005415CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162
189Ionis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗
190ImmunityBio, Inc., Section 10b CEO totalDEF 14A2026-04-300001326110-26-000049CEO total compensation as printed in ImmunityBio, Inc.'s own proxy. As printed: 12,716,953. Filing ↗machine: t62 · r3 · c22 · span 544834–544844
191CYTOKINETICS INC (subject), Section 10b CEO totalDEF 14A2026-04-170001140361-26-015364CEO total compensation as printed in CYTOKINETICS INC's own proxy. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103
192Crinetics Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-290001658247-26-000030CEO total compensation as printed in Crinetics Pharmaceuticals, Inc.'s own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460
193Ultragenyx Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-03-270001308179-26-000174CEO total compensation as printed in Ultragenyx Pharmaceuticals Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007
194Apellis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
195Axsome Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
196Intra-Cellular Therapies, Inc., Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
197Arrowhead Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-01-270000879407-26-000019CEO total compensation as printed in Arrowhead Pharmaceuticals, Inc.'s own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484
198Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
199ACADIA Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗
200Sarepta Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177247CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404
201Denali Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614
202Section 10a, ACADIA Pharmaceuticals Inc. reciprocityDEF 14A—0001193125-26-174163ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
203Section 10a, Axsome Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177610Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
204Section 10a, BridgeBio Pharma, Inc. reciprocityDEF 14A—0001140361-26-016723BridgeBio Pharma, Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
205Section 10a, Crinetics Pharmaceuticals, Inc. reciprocityDEF 14A—0001658247-26-000030Crinetics Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
206Section 10a, Halozyme Therapeutics, Inc. reciprocityDEF 14A—0001159036-26-000041Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
207Section 10a, INSMED Inc. reciprocityDEF 14A—0001104506-26-000022INSMED Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
208Section 10a, Madrigal Pharmaceuticals, Inc. reciprocityDEF 14A—0001308179-26-000352Madrigal Pharmaceuticals, Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
209Section 10a, Sarepta Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177247Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
210Section 10a, Vaxcyte, Inc. reciprocityDEF 14A—0001193125-26-173672Vaxcyte, Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
211Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
212Section 10a, Ultragenyx Pharmaceuticals Inc. reciprocityDEF 14A—0001308179-26-000174Ultragenyx Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
213Section 10a, Apellis Pharmaceuticals, Inc. reciprocityDEF 14A—0000950170-25-056966Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
214Section 10a, Blueprint Medicines Corporation reciprocityDEF 14A—0001558370-25-005415Blueprint Medicines Corporation's most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
215Section 10a, Intra-Cellular Therapies, Inc. reciprocityDEF 14A—0001628280-24-018986Intra-Cellular Therapies, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
216Section 10a, Immunovant, Inc. reciprocityDEF 14A—0001764013-26-000092Immunovant, Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
217Section 10a, Denali Therapeutics Inc. reciprocityDEF 14A—0001714899-26-000054Denali Therapeutics Inc. names CYTOKINETICS INC in its own disclosed peer group (read from its most recent proxy). Filing ↗
218Section 10a, ImmunityBio, Inc. reciprocityDEF 14A—0001326110-26-000049ImmunityBio, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
219Section 10a, Ionis Pharmaceuticals, Inc. reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗
220Section 10a, Arrowhead Pharmaceuticals, Inc. reciprocityDEF 14A—0000879407-26-000019Arrowhead Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include CYTOKINETICS INC. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the CYTOKINETICS INC Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
CYTK Peer Teardown Report